A COVID-19 vaccine that could provide protection against existing and future strains of the COVID-19 coronavirus, and other coronaviruses, and cost about $1 a dose has shown promising results in early testing.
Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations. In a new paper in International Journal of Infectious Diseases, medical experts in Italy and Australia examined levels of a chemical called serum amyloid A (SAA), a protein synthesised in the liver which can spike up to 1,000-fold within the first 24-48 hours of an infection.
One of the most comprehensive statistical analyses of drivers of food insecurity across 65 countries has concluded that household income consistently explains more discrepancy in food security than any other factor, including agricultural land resources and production.
Now that federal funding is flowing again for research on firearm injury prevention, some of the few already-funded researchers doing work in this area share new results and look ahead.
An estimated 334,000 COVID-19 cases are attributable to meatpacking plants, resulting in $11.2 billion in economic damage, according to a new study led by a researcher at the University of California, Davis.
The results of the first clinical trial of a new vaccine for a neglected tropical disease have demonstrated that it is safe and induces immune responses in patients with the infection.
What The Study Did: Researchers estimated the risk of suicide among nurses and physicians compared to the general population in the United States.
What The Study Did: Data from the Ohio Department of Health were used to evaluate changes in drug overdose mortality in that state by type of drug and age of the user during the first seven months of the COVID-19 epidemic.
Lundquist Investigator Dr. Dong Chang and his colleagues' study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study - "Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments" - found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.
ABCC1 has been shown in laboratory models to remove a plaque-forming protein known as amyloid beta from specialized endothelial cells that surround and protect the brain and cerebral spinal cord. Building on previous studies, TGen conducted a series of pre-clinical genomic laboratory experiments. Results suggest that ABCC1 not only could export Abeta out of the brain, but that increasing the expression of ABCC1 could reduce Abeta production, thus preventing, or delaying, the onset of Alzheimer's.